Yes, absolutely positively quite possible! A Hikma loss would be more than a legal footnote for Amarin Corporation — it would be a narrative shock. The moment litigation fog lifts, AMRN flips from “distressed battleground stock” to a clean, cash-generating global cardiovascular franchise with stabilized U.S. economics and growing ROW momentum. In that setup, even a credible takeover rumor — not a deal, just interest — is enough to ignite a violent squeeze, given the asymmetric positioning, low float, and years of bearish consensus. Big pharma doesn’t need Vascepa to be perfect; it just needs to be predictable, and a Hikma defeat delivers exactly that. A strategic buyer paying $5–10B for a de-risked, globally scaled CV asset with lifecycle optionality is entirely rational — and the market will front-run that possibility long before any press release hits. In this tape, perception moves faster than fundamentals, and once the bear thesis breaks, price discovery won’t be polite.
Market Data 
Markets 
AI
